Segall Bryant & Hamill LLC Acquires 14,668 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Segall Bryant & Hamill LLC boosted its holdings in Blueprint Medicines Co. (NASDAQ:BPMC) by 11.6% in the third quarter, Holdings Channel reports. The firm owned 141,622 shares of the biotechnology company’s stock after purchasing an additional 14,668 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in Blueprint Medicines were worth $13,100,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in shares of Blueprint Medicines by 3.2% in the 1st quarter. Vanguard Group Inc. now owns 6,309,977 shares of the biotechnology company’s stock valued at $598,564,000 after acquiring an additional 195,007 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in Blueprint Medicines by 15.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,250,823 shares of the biotechnology company’s stock valued at $592,954,000 after purchasing an additional 821,868 shares in the last quarter. American Century Companies Inc. increased its position in shares of Blueprint Medicines by 4.2% during the 2nd quarter. American Century Companies Inc. now owns 802,733 shares of the biotechnology company’s stock worth $86,519,000 after purchasing an additional 32,600 shares during the last quarter. Millennium Management LLC raised its stake in shares of Blueprint Medicines by 540.0% during the 2nd quarter. Millennium Management LLC now owns 627,626 shares of the biotechnology company’s stock worth $67,646,000 after purchasing an additional 529,566 shares in the last quarter. Finally, Hood River Capital Management LLC boosted its holdings in shares of Blueprint Medicines by 7.0% in the 2nd quarter. Hood River Capital Management LLC now owns 502,820 shares of the biotechnology company’s stock valued at $54,194,000 after buying an additional 32,694 shares during the last quarter.

Insider Buying and Selling

In other news, insider Fouad Namouni sold 3,633 shares of the company’s stock in a transaction that occurred on Thursday, October 3rd. The shares were sold at an average price of $89.32, for a total transaction of $324,499.56. Following the completion of the sale, the insider now owns 69,070 shares of the company’s stock, valued at approximately $6,169,332.40. This represents a 5.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 4.21% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on BPMC shares. JMP Securities restated a “market outperform” rating and set a $125.00 target price on shares of Blueprint Medicines in a report on Monday. Baird R W upgraded shares of Blueprint Medicines to a “strong-buy” rating in a research note on Friday, August 2nd. UBS Group started coverage on shares of Blueprint Medicines in a research note on Thursday, October 24th. They issued a “neutral” rating and a $88.00 target price for the company. Barclays lifted their price target on Blueprint Medicines from $75.00 to $105.00 and gave the stock an “equal weight” rating in a report on Monday, July 29th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research report on Friday, November 15th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $122.11.

Blueprint Medicines Stock Performance

Shares of NASDAQ:BPMC opened at $94.81 on Thursday. Blueprint Medicines Co. has a 12-month low of $64.79 and a 12-month high of $121.90. The company’s 50 day moving average price is $90.00 and its two-hundred day moving average price is $98.70. The firm has a market cap of $6.02 billion, a PE ratio of -44.93 and a beta of 0.59. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.08. The business had revenue of $128.20 million for the quarter, compared to the consensus estimate of $127.56 million. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The firm’s quarterly revenue was up 126.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($2.20) earnings per share. Equities research analysts predict that Blueprint Medicines Co. will post -3.61 earnings per share for the current year.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.